Recent clinical trials of the anti-PD-1 antibody nivolumab report that tumor cell PD-L1 expression correlates with response to nivolumab in non-squamous but not the squamous subtype of NSCLC (Borghaei et al., 2015, Brahmer et al., 2015). Here, CD274 is linked to non-small cell lung carcinoma.